Chembio Diagnostics, Inc. (CEMI): Price and Financial Metrics
CEMI Price/Volume Stats
| Current price | $0.46 | 52-week high | $1.24 |
| Prev. close | $0.45 | 52-week low | $0.19 |
| Day low | $0.45 | Volume | 351,600 |
| Day high | $0.46 | Avg. volume | 661,416 |
| 50-day MA | $0.43 | Dividend yield | N/A |
| 200-day MA | $0.45 | Market Cap | 16.71M |
CEMI Stock Price Chart Interactive Chart >
CEMI Stock Summary
- CEMI has a higher market value than just 7.32% of US stocks; more precisely, its current market capitalization is $16,967,346.
- With a price/sales ratio of 0.34, CHEMBIO DIAGNOSTICS INC has a higher such ratio than just 12.45% of stocks in our set.
- In terms of volatility of its share price, CEMI is more volatile than 91.14% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to CHEMBIO DIAGNOSTICS INC are FOXF, CTS, TWOU, PRTK, and IRIX.
- Visit CEMI's SEC page to see the company's official filings. To visit the company's web site, go to chembio.com.
CEMI Valuation Summary
- In comparison to the median Healthcare stock, CEMI's price/earnings ratio is 102.93% lower, now standing at -0.7.
- CEMI's EV/EBIT ratio has moved up 4.9 over the prior 229 months.
Below are key valuation metrics over time for CEMI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CEMI | 2023-04-21 | 0.3 | 0.9 | -0.7 | -1.1 |
| CEMI | 2023-04-20 | 0.3 | 0.9 | -0.7 | -1.1 |
| CEMI | 2023-04-19 | 0.3 | 0.9 | -0.7 | -1.1 |
| CEMI | 2023-04-18 | 0.3 | 0.9 | -0.7 | -1.1 |
| CEMI | 2023-04-17 | 0.3 | 0.9 | -0.7 | -1.2 |
| CEMI | 2023-04-14 | 0.3 | 0.9 | -0.7 | -1.1 |
CEMI Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at -8.18%.
- Its 5 year cash and equivalents growth rate is now at 101.31%.
- Its 2 year net income to common stockholders growth rate is now at -140.85%.
The table below shows CEMI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 59.75173 | -16.59715 | -36.40867 |
| 2022-06-30 | 60.61002 | -19.7792 | -36.07572 |
| 2022-03-31 | 57.9107 | -27.99341 | -38.19366 |
| 2021-12-31 | 47.81845 | -30.88572 | -33.90353 |
| 2021-09-30 | 37.47188 | -28.89083 | -27.06958 |
| 2021-06-30 | 35.68591 | -27.46491 | -26.24253 |
CEMI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CEMI has a Quality Grade of F, ranking ahead of 4.04% of graded US stocks.
- CEMI's asset turnover comes in at 0.59 -- ranking 57th of 682 Pharmaceutical Products stocks.
- NEOG, CLVS, and ENDP are the stocks whose asset turnover ratios are most correlated with CEMI.
The table below shows CEMI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.590 | 0.400 | -0.488 |
| 2021-03-31 | 0.508 | 0.329 | -0.488 |
| 2020-12-31 | 0.492 | 0.265 | -0.504 |
| 2020-09-30 | 0.457 | 0.251 | -0.430 |
| 2020-06-30 | 0.472 | 0.265 | -0.404 |
| 2020-03-31 | 0.642 | 0.334 | -0.343 |
CEMI Price Target
For more insight on analysts targets of CEMI, see our CEMI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $8.00 | Average Broker Recommendation | 1.83 (Hold) |
Chembio Diagnostics, Inc. (CEMI) Company Bio
Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. The company was founded in 1985 and is based in Medford, New York.
Latest CEMI News From Around the Web
Below are the latest news stories about CHEMBIO DIAGNOSTICS INC that investors may wish to consider to help them evaluate CEMI as an investment opportunity.
Biosynex Completes Acquisition of Chembio Diagnostics, Inc.Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The comp |
Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023Failure to tender shares could result in the termination of the proposed merger between Chembio and BiosynexMEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 Fellow Chembio Stockholders, We strongly urge you to tender your shares of common stock of Chembio Diagno |
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasd |
Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10, 2023 Fellow Chembio Stockholders, As previously communicated, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 31, 2023, |
Chembio’s CEO Letter to StockholdersReminder to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023MEDFORD, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 3, 2023 Fellow Chembio Stockholders, As previously communicated, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agree |
CEMI Price Returns
| 1-mo | N/A |
| 3-mo | 3.30% |
| 6-mo | 53.69% |
| 1-year | -38.38% |
| 3-year | -94.80% |
| 5-year | -95.53% |
| YTD | 109.38% |
| 2022 | -80.73% |
| 2021 | -76.00% |
| 2020 | 4.17% |
| 2019 | -19.43% |
| 2018 | -30.98% |
Continue Researching CEMI
Want to see what other sources are saying about Chembio Diagnostics Inc's financials and stock price? Try the links below:Chembio Diagnostics Inc (CEMI) Stock Price | Nasdaq
Chembio Diagnostics Inc (CEMI) Stock Quote, History and News - Yahoo Finance
Chembio Diagnostics Inc (CEMI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...